Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.72 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.72 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.72 |
| ▸ | PREP | P48147 | 4/20 | 0.51 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16192794 | 1.00 | CHRM2 (0.72) | CHRM2CHRM1CHRM3PREPHSD11B1 | |
| SCHEMBL961190 | 1.00 | CHRM2 (0.72) | CHRM2CHRM1CHRM3PREPHSD11B1 | |
| SCHEMBL3460434 | 1.00 | CHRM2 (0.72) | CHRM2CHRM1CHRM3PREPHSD11B1 | |
| SCHEMBL3460435 | 1.00 | CHRM2 (0.72) | CHRM2CHRM1CHRM3PREPHSD11B1 | |
| SCHEMBL8011988 | 1.00 | CHRM2 (0.72) | CHRM2CHRM1CHRM3PREPHSD11B1 | |
| SCHEMBL25247226 | 1.00 | CHRM2 (0.72) | CHRM2CHRM1CHRM3PREPHSD11B1 | |
| SCHEMBL961189 | 1.00 | CHRM2 (0.72) | CHRM2CHRM1CHRM3PREPHSD11B1 | |
| Acetic Acid SCHEMBL30147258 | 0.95 | CHRM2 (0.66) | CHRM2CHRM1CHRM3PREPHSD11B1 | |
| SCHEMBL8185274 | 0.93 | CHRM2 (0.63) | CHRM2CHRM1CHRM3PREPHSD11B1 | |
| SCHEMBL17593204 | 0.93 | CHRM2 (0.63) | CHRM2CHRM1CHRM3PREPHSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 365 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4076459-B1 | PRMT5 INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2026-04-29 | — | — | EP | disclosed |
| US-12595248-B2 | PRMT5 inhibitors | MERCK SHARP & DOHME LLC (US) | 2026-04-07 | — | — | US | disclosed |
| EP-4705281-A1 | COMPOUNDS FOR TREATING CANCER | Genesis Molecular AI, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| US-12565476-B2 | 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric SHP2 inhibitors | Revolution Medicines, Inc. (US) | 2026-03-03 | — | — | US | disclosed |
| EP-4463457-B1 | PYRROLO[1,2-B]-2-PYRIDAZINONE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | SUVEN LIFE SCIENCES LTD (IN) | 2026-02-04 | — | — | EP | disclosed |
| US-12338226-B2 | Substituted benzodiazoles and use thereof in therapy | THOMAS HELLEDAYS STIFTELSE FOR MEDICINSK FORSKNING (SE) | 2025-06-24 | — | — | US | disclosed |
| CN-116003441-B | Heteroaromatic derivative regulator, preparation method and application thereof | 江苏豪森药业集团有限公司 | 2025-06-10 | — | — | CN | disclosed |
| US-12275746-B2 | Pyrrolo[1,2-b]-2-pyridazinone compounds as 5-HT4 receptor agonists | SUVEN LIFE SCIENCES LIMITED (IN) | 2025-04-15 | — | — | US | disclosed |
| US-12252484-B2 | Pyrazolopyridine compounds for the treatment of autoimmune disease | HOFFMANN-LA ROCHE INC. (US) | 2025-03-18 | — | — | US | disclosed |
| US-20250019386-A1 | PYRROLO[1,2-b]-2-PYRIDAZINONE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | SUVEN LIFE SCIENCES LIMITED (IN) | 2025-01-16 | — | — | US | disclosed |
| US-20030220361-A1 | Administering together tiotropium salt and substituted 3-amidopyridine derivatives for treating inflammation, allergic and respiratory diseases | PFIZER INC. | 2003-11-27 | — | — | US | disclosed |
| US-20030220366-A1 | Nicotinamide derivatives useful as PDE4 inhibitors | PFIZER INC. | 2003-11-27 | — | — | US | disclosed |
| WO-2003068233-A1 | NICOTINAMIDE DERIVATIVES AND A TIOTROPIUM SALT IN COMBINATION FOR THE TREATMENT OF E.G. INFLAMMATORY, ALLERGIC AND RESPIRATORY DISEASES | PFIZER LIMITED (GB) | 2003-08-21 | — | — | WO | disclosed |
| WO-2003068235-A1 | NICOTINAMIDE DERIVATIVES USEFUL AS PDE4 INHIBITORS | PFIZER LIMITED (GB) | 2003-08-21 | — | — | WO | disclosed |
| US-6531484-B2 | Viricides for preventing infection by HIV, treating infection by HIV, delaying of the onset of AIDS, or treating AIDS | MERCK & CO., INC. | 2003-03-11 | — | — | US | disclosed |
| EP-0710662-B1 | QUINOLINECARBOXYLIC ACID DERIVATIVE | SYNGENTA LTD (GB) | 2001-04-04 | — | — | EP | disclosed |
| EP-1018513-A2 | Quinolinecarboxylic acid derivatives | ZENECA LIMITED (GB) | 2000-07-12 | — | — | EP | disclosed |
| US-6051575-A | RESPIRATORY SYSTEM DISORDERS; SKIN DISORDERS; ANTIINFLAMMATORY AGENTS | SCHERING CORPORATION (US) | 2000-04-18 | — | — | US | disclosed |
| US-5968929-A | USEFUL IN THE TREATMENT OF CHRONIC AIRWAY DISEASES SUCH AS ASTHMA | SCHERING CORPORATION (US) | 1999-10-19 | — | — | US | disclosed |
| EP-0710662-A1 | QUINOLINECARBOXYLIC ACID DERIVATIVE | TAISHO PHARMACEUTICAL CO. LTD (JP) | 1996-05-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12595248-B2 | PRMT5 inhibitors | PRMT5, PRMT1, PRMT6 | CHRM2 1785/4885CHRM1 859/4885CHRM3 1751/4885 |
| US-12275746-B2 | Pyrrolo[1,2-b]-2-pyridazinone compounds as 5-HT4 receptor agonists | HTR4, HTR5A, HTR1B | CHRM2 492/4885CHRM1 282/4885CHRM3 477/4885 |
| US-12252484-B2 | Pyrazolopyridine compounds for the treatment of autoimmune disease | KCNJ1, KCNJ11, SSB | CHRM2 130/4885CHRM1 153/4885CHRM3 352/4885 |
| US-20030220361-A1 | Administering together tiotropium salt and substituted 3-amidopyridine derivatives for treating inflammation, allergic and respiratory diseases | NNT, IL5, NOX5 | CHRM2 86/4885CHRM1 123/4885CHRM3 6/4885 |
| US-20030220366-A1 | Nicotinamide derivatives useful as PDE4 inhibitors | PDE4A, PDE4B, PDE4C | CHRM2 1570/4885CHRM1 1880/4885CHRM3 1489/4885 |
| US-20250019386-A1 | PYRROLO[1,2-b]-2-PYRIDAZINONE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | HTR4, HTR5A, HTR1B | CHRM2 492/4885CHRM1 282/4885CHRM3 477/4885 |
| US-12565476-B2 | 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric SHP2 inhibitors | PTPN5, PTPN6, PTPN2 | CHRM2 2065/4885CHRM1 2542/4885CHRM3 1608/4885 |
| US-12338226-B2 | Substituted benzodiazoles and use thereof in therapy | XDH, CYP11B2, CYP4X1 | CHRM2 1203/4885CHRM1 556/4885CHRM3 2016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.